
Opinion|Videos|January 23, 2025
Case 2 Presentation: mCRPC
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, discusses how the presentation of a patient with metastatic castration-resistant prostate cancer (mCRPC) involves evaluating factors such as disease progression despite androgen deprivation therapy, symptoms, prior treatments, and performance status to guide the selection of appropriate therapeutic strategies for managing this advanced disease state.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Would you consider adding chemotherapy to a doublet regimen on an as-needed basis?
Advertisement
Related to this article

Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable in DLL3-high tumors.

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with similar safety across subgroups.

Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and gaps in clinical evidence.

The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

The Community Oncology Alliance said CMS’s final 2027 outpatient rule pays 340B hospitals ASP minus 28% for drugs, but physician payment cuts still threaten practices.

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer progression-free survival after retreatment.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
COA Backs 340B Payment Cut in 2027 Final Rules, Warns of Physician Cuts
4
Moving Past Empiric Chemotherapy in Platinum-Sensitive Ovarian Cancer
5
